Brief: Symbiotec Pharmalab Unit Enters Into Strategic Commercialization Agreement
30/09/2026 16:33
BRIEF-Symbiotec Pharmalab Unit Enters Into Strategic Commercialization Agreement Sept 30 (Reuters) - Symbiotec Pharmalab Limited SYMI.NS:
SYMBIOTEC PHARMALAB - UNIT ENTERS INTO STRATEGIC COMMERCIALIZATION AGREEMENT
SYMBIOTEC PHARMALAB - AGREEMENT GRANTS EXCLUSIVE RIGHTS TO DISTRIBUTE TWO DCV INJECTABLE PRODUCTS IN U.S.
Source text: ID:nNSE5M0nh2
Further company coverage: SYMI.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Symbiotec Pharmalab
See all newsIndia's Symbiotec Pharmalab rises on US drug distribution deal
Brief: Symbiotec Pharmalab Unit Enters Into Strategic Commercialization Agreement
Brief: Symbiotec Pharmalab Receives U.S. FDA Eir For Pithampur Facility With Vai Status
India's Symbiotec Pharmalab declines after Q1 profit fall
India's Symbiotec Pharmalab rises after muted debut, valued at $779 million